HRP20070286T3 - Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti - Google Patents

Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti

Info

Publication number
HRP20070286T3
HRP20070286T3 HR20070286T HRP20070286T HRP20070286T3 HR P20070286 T3 HRP20070286 T3 HR P20070286T3 HR 20070286 T HR20070286 T HR 20070286T HR P20070286 T HRP20070286 T HR P20070286T HR P20070286 T3 HRP20070286 T3 HR P20070286T3
Authority
HR
Croatia
Prior art keywords
oxytocyn
antagonists
substituted diketopiperazines
diketopiperazines
substituted
Prior art date
Application number
HR20070286T
Other languages
English (en)
Inventor
Liddle John
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HRP20070286T3 publication Critical patent/HRP20070286T3/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Spoj formule (1) naznačen time što R1 je 2-indanil, R2 je 1-metilpropil, R3 je 2-metil-1,3-oksazol-4-il, a R4 i R5 zajedno s atomom dušika na kojeg su vezani predstavljaju morfolino. Patent sadrži još 8 patentnih zahtjeva.
HR20070286T 2003-06-24 2007-06-29 Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti HRP20070286T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314738A GB0314738D0 (en) 2003-06-24 2003-06-24 Novel compounds
PCT/EP2004/006814 WO2005000840A1 (en) 2003-06-24 2004-06-22 Substituted diketopiperazines and their use as oxytocin antagonists

Publications (1)

Publication Number Publication Date
HRP20070286T3 true HRP20070286T3 (hr) 2007-08-31

Family

ID=27637257

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070286T HRP20070286T3 (hr) 2003-06-24 2007-06-29 Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti

Country Status (31)

Country Link
US (6) US8071594B2 (hr)
EP (1) EP1641787B1 (hr)
JP (1) JP5128126B2 (hr)
KR (1) KR101131378B1 (hr)
CN (2) CN101597282A (hr)
AR (1) AR044869A1 (hr)
AT (1) ATE361295T1 (hr)
AU (1) AU2004251868B2 (hr)
BR (1) BRPI0411729A (hr)
CA (1) CA2530310C (hr)
CY (1) CY1107703T1 (hr)
DE (1) DE602004006268T2 (hr)
DK (1) DK1641787T3 (hr)
EG (1) EG24929A (hr)
ES (1) ES2285474T3 (hr)
GB (1) GB0314738D0 (hr)
HK (1) HK1088910A1 (hr)
HR (1) HRP20070286T3 (hr)
IL (1) IL172529A (hr)
IS (1) IS2463B (hr)
MA (1) MA27887A1 (hr)
MX (1) MXPA05014068A (hr)
MY (1) MY140653A (hr)
NO (1) NO332677B1 (hr)
NZ (1) NZ544006A (hr)
PL (1) PL1641787T3 (hr)
PT (1) PT1641787E (hr)
RU (1) RU2343152C2 (hr)
TW (1) TWI340745B (hr)
WO (1) WO2005000840A1 (hr)
ZA (1) ZA200509890B (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
WO2011051814A1 (en) 2009-10-30 2011-05-05 Glaxo Group Limited Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione
KR20170029507A (ko) 2014-06-16 2017-03-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조기 진통의 치료를 위한 레토시반
PL3400217T3 (pl) 2016-01-04 2022-07-04 Merck Serono S.A. L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystaliczna
KR20230165386A (ko) 2016-07-21 2023-12-05 옵스에파 에스에이 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투약 레지멘
CN106674031A (zh) * 2016-11-18 2017-05-17 浙江工业大学 R‑2‑二氢茚氨酸的制备方法
CA3149898A1 (en) 2019-09-03 2021-03-11 Ernest Loumaye Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CA3167121A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
US5968938A (en) * 1997-06-18 1999-10-19 Merck & Co., Inc. Piperazine oxytocin receptor antagonists
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
ZA99607B (en) 1998-01-27 1999-07-27 Rhone Poulenc Rorer Pharma Substituted oxoazaheterocyclyl factor xa inhibitors.
WO1999038844A1 (en) 1998-01-29 1999-08-05 Aventis Pharmaceuticals Products Inc. Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US20030229001A1 (en) 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
CN103930132A (zh) 2011-09-27 2014-07-16 拜奥迈德瓦利探索有限公司 治疗胶质瘤的组合物和方法

Also Published As

Publication number Publication date
IL172529A (en) 2011-06-30
HK1088910A1 (en) 2006-11-17
IL172529A0 (en) 2006-04-10
DE602004006268T2 (de) 2008-01-10
US20130102783A1 (en) 2013-04-25
MXPA05014068A (es) 2006-03-02
NO332677B1 (no) 2012-12-03
TW200524917A (en) 2005-08-01
EP1641787B1 (en) 2007-05-02
PL1641787T3 (pl) 2007-08-31
NO20060383L (no) 2006-01-24
TWI340745B (en) 2011-04-21
BRPI0411729A (pt) 2006-08-08
CA2530310C (en) 2012-01-03
NZ544006A (en) 2008-12-24
CY1107703T1 (el) 2013-04-18
CA2530310A1 (en) 2005-01-06
ZA200509890B (en) 2006-07-26
MY140653A (en) 2010-01-15
DE602004006268D1 (de) 2007-06-14
CN1812987A (zh) 2006-08-02
US20150105387A1 (en) 2015-04-16
GB0314738D0 (en) 2003-07-30
US8071594B2 (en) 2011-12-06
JP5128126B2 (ja) 2013-01-23
US20070149524A1 (en) 2007-06-28
JP2009513484A (ja) 2009-04-02
ES2285474T3 (es) 2007-11-16
EP1641787A1 (en) 2006-04-05
WO2005000840A1 (en) 2005-01-06
RU2343152C2 (ru) 2009-01-10
CN100404532C (zh) 2008-07-23
AU2004251868A1 (en) 2005-01-06
WO2005000840A8 (en) 2005-05-19
IS2463B (is) 2008-11-15
DK1641787T3 (da) 2007-09-17
KR20060024440A (ko) 2006-03-16
EG24929A (en) 2011-01-05
CN101597282A (zh) 2009-12-09
AR044869A1 (es) 2005-10-05
US9452169B2 (en) 2016-09-27
US8937179B2 (en) 2015-01-20
KR101131378B1 (ko) 2012-04-04
MA27887A1 (fr) 2006-05-02
ATE361295T1 (de) 2007-05-15
US8357685B2 (en) 2013-01-22
US20120004229A1 (en) 2012-01-05
IS8248A (is) 2006-01-20
US20160074413A1 (en) 2016-03-17
RU2006101859A (ru) 2006-06-10
AU2004251868B2 (en) 2009-01-22
US20140058105A1 (en) 2014-02-27
PT1641787E (pt) 2007-08-01

Similar Documents

Publication Publication Date Title
HRP20070286T3 (hr) Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
DE60307179D1 (de) Vor UV-Strahlen schützende Zusammensetzungen
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
NO20062644L (no) DPP-IV inhibitorer
CY1110355T1 (el) Ενεργοποιητης του ενεργοποιουμενου απο πολλαπλασιαστη υπεροξυσωματων υποδοχεα δ
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
HRP20080602T3 (hr) Amidometil-supstituirani derivati 2-(4-sulfonilamin)-3,4-dihidro-2h-kromen-6, postupci njihovog dobivanja i međuproizvodi, te lijekovi koji sadrže teveze
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
PA8573501A1 (es) Derivados de benzoxazina y su empleo
SE0300092D0 (sv) Novel compounds
RS50229B (sr) Analozi vitamina d3
DE602004029355D1 (de) Sulfopyrrolderivate
TW200505446A (en) Inhibitor of cox
EA200700179A1 (ru) Производные пиррола, их получение и их применение в терапии
HRP20020440B1 (hr) 1-aza-dibenzoazuleni kao inhibitori produkcije faktora nekroze tumora i međuprodukti za njihovu pripravu
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
HUP0500082A2 (hu) Endotelin-antagonista aktivitású alkán-szulfonamidok és alkalmazásuk
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
RS50791B (sr) Farmaceutske kombinacije zasnovane na derivatima piridoindolona